How This Works
Retatrutide is a first-in-class triple agonist that simultaneously activates three key metabolic hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple mechanism produces synergistic effects on appetite suppression, energy expenditure, and glucose metabolism that exceed single or dual agonists.
The GLP-1 component reduces appetite and slows gastric emptying; GIP enhances insulin secretion and may support fat metabolism; glucagon receptor activation increases energy expenditure and promotes fat oxidation. With an extended half-life of approximately 6 days, retatrutide enables convenient once-weekly dosing while maintaining therapeutic levels.
In clinical trials, participants receiving 12 mg weekly retatrutide lost an average of 24% of their body weight over 48 weeks. In adults with type 2 diabetes, retatrutide (up to 12 mg weekly) achieved approximately 17% weight loss at 36 weeks alongside HbA1c reductions of approximately 2.0% compared to placebo. A 2025 meta-analysis of three trials (878 participants) confirmed retatrutide achieved significantly greater weight reduction than placebo (mean difference approximately 14% of body weight) with no significant increase in overall adverse events
Potential Benefits & Side Effects
Potential Benefits
Substantial weight loss: Up to 24% reduction in body weight at 48 weeks with 12 mg weekly dosing.
Glycemic improvement: Significant HbA1c reductions (approximately 2.0%) in adults with type 2 diabetes.
Metabolic benefits: Improvements in lipid profiles, blood pressure, and cardiovascular risk markers.
Convenient dosing: Once-weekly subcutaneous administration improves adherence compared to daily regimens.
Common Side Effects
Gastrointestinal effects: Nausea, diarrhea, vomiting, and constipation are the most common adverse events; typically mild-to-moderate and diminish over time.
Starting at 2 mg weekly (versus 4 mg) significantly reduces initial GI adverse events.
Injection site reactions: Mild redness, swelling, or discomfort at injection sites may occur; rotate sites to minimize.
Overall safety profile: Meta-analysis found no significant increase in overall adverse events compared to placebo.
Dosage Guide: http://help.datapeptides.com/en/articles/15073734-retatrutide-10mg-vial-dosage-protocol
Disclaimer:
The information provided in this article is for educational and informational purposes only and is not intended as medical advice. These statements have not been evaluated by the FDA or Health Canada. Peptides and other compounds discussed are intended for research purposes only and are not approved for human consumption unless prescribed by a licensed medical professional. Always consult your healthcare provider before starting any new protocol, supplement, or treatment.